[{"id":"08e8d834-7d1c-43f8-b2b4-1023ee00f03e","acronym":"X31025","url":"https://clinicaltrials.gov/study/NCT03154294","created_at":"2025-09-13T10:56:31.458Z","updated_at":"2025-09-13T10:56:31.458Z","phase":"Phase 1","brief_title":"Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors","source_id_and_acronym":"NCT03154294 - X31025","lead_sponsor":"Avera McKennan Hospital \u0026 University Health Center","biomarkers":" PI3K","pipe":"","alterations":" ","tags":["PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • sapanisertib (CB-228) • serabelisib (MLN1117)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 07/06/2017","start_date":" 07/06/2017","primary_txt":" Primary completion: 11/20/2020","primary_completion_date":" 11/20/2020","study_txt":" Completion: 11/20/2022","study_completion_date":" 11/20/2022","last_update_posted":"2024-07-26"},{"id":"3488cb10-49e7-486c-92f8-ae33fb27ea85","acronym":"","url":"https://clinicaltrials.gov/study/NCT05300048","created_at":"2022-03-29T13:53:03.511Z","updated_at":"2024-07-02T16:35:19.679Z","phase":"Phase 1","brief_title":"Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations","source_id_and_acronym":"NCT05300048","lead_sponsor":"Faeth Therapeutics","biomarkers":" PIK3CA • PTEN","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • serabelisib (MLN1117)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 04/22/2022","start_date":" 04/22/2022","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-02-13"},{"id":"a49319c7-fc86-477e-9d18-340184f8a72b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03193853","created_at":"2021-01-18T15:44:59.657Z","updated_at":"2025-02-25T14:50:33.000Z","phase":"Phase 2","brief_title":"TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer","source_id_and_acronym":"NCT03193853","lead_sponsor":"Joyce O'Shaughnessy","biomarkers":" AR","pipe":" | ","alterations":" AR negative","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • albumin-bound paclitaxel • sapanisertib (CB-228) • serabelisib (MLN1117)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 07/18/2017","start_date":" 07/18/2017","primary_txt":" Primary completion: 03/17/2020","primary_completion_date":" 03/17/2020","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2023-08-07"},{"id":"3050983b-af30-46fd-910e-e5f5087885ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT02724020","created_at":"2021-01-18T13:19:55.870Z","updated_at":"2024-07-02T16:36:20.474Z","phase":"Phase 2","brief_title":"MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma","source_id_and_acronym":"NCT02724020","lead_sponsor":"Millennium Pharmaceuticals, Inc.","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • sapanisertib (CB-228) • serabelisib (MLN1117)"],"overall_status":"Completed","enrollment":" Enrollment 96","initiation":"Initiation: 06/30/2016","start_date":" 06/30/2016","primary_txt":" Primary completion: 02/03/2020","primary_completion_date":" 02/03/2020","study_txt":" Completion: 10/13/2020","study_completion_date":" 10/13/2020","last_update_posted":"2021-11-19"},{"id":"1b9c92f0-7afe-4a9a-922c-f98ba5e3cba1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04073680","created_at":"2021-01-18T19:57:13.292Z","updated_at":"2024-07-02T16:36:44.865Z","phase":"Phase 1b/2","brief_title":"A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04073680","lead_sponsor":"Petra Pharma","biomarkers":" KRAS • PIK3CA","pipe":" | ","alterations":" KRAS mutation • PIK3CA mutation","tags":["KRAS • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e serabelisib (MLN1117)"],"overall_status":"Unknown status","enrollment":" Enrollment 60","initiation":"Initiation: 09/01/2020","start_date":" 09/01/2020","primary_txt":" Primary completion: 07/15/2021","primary_completion_date":" 07/15/2021","study_txt":" Completion: 12/30/2021","study_completion_date":" 12/30/2021","last_update_posted":"2020-05-21"},{"id":"3deff03e-ff7c-4fa2-876e-abcb0059ac96","acronym":"","url":"https://clinicaltrials.gov/study/NCT01449370","created_at":"2021-01-18T06:00:55.197Z","updated_at":"2024-07-02T16:37:24.603Z","phase":"Phase 1","brief_title":"Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer","source_id_and_acronym":"NCT01449370","lead_sponsor":"Millennium Pharmaceuticals, Inc.","biomarkers":" PIK3CA","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e serabelisib (MLN1117)"],"overall_status":"Completed","enrollment":" Enrollment 125","initiation":"Initiation: 10/01/2011","start_date":" 10/01/2011","primary_txt":" Primary completion: 07/01/2015","primary_completion_date":" 07/01/2015","study_txt":" Completion: 01/01/2016","study_completion_date":" 01/01/2016","last_update_posted":"2017-03-09"}]